Search

Objective: To explore the therapeutic effect of combination of Gusegzumab and Xiaobi Tang on psoriasis vulgaris and its impact on blood cell derived inflammatory markers. Methods: 86 patients with psoriasis vulgaris admitted to our hospital from October 2020 to October 2023 were selected. They were divided into an observation group and a matched group, with 43 patients in each group. The matched group received treatment with Gusegzumab, while the observation group received treatment with Gusegzumab combined with Xiaobi Tang. Compare the clinical efficacy of two groups of patients, including changes in blood cell derived inflammation indicators, changes in Th17/Treg cell levels, and changes in liver and kidney function before and Post-treatment. Results: The total effective rate of the observation group was higher than that of the matched group(P<0.05); Pretherapy, there was no difference in the levels of NLPR, dNLR, AISI, SII, SIRI, MLR, PLR, and NLR between the two groups of patients(P>0.05). Post-treatment, the levels in both groups of patients decreased. The observation group was lower than the matched group(P<0.05); Pretherapy, there was no difference in Treg, Th17, and Th17/Treg between the two groups of patients(P>0.05). Post-treatment, there were differences between the two groups, and between the observation group and the matched group(P<0.05); There was no difference in the expression levels of liver function related indicators such as alkaline phosphatase(ALP), glutamic pyruvic transaminase(ALT), glutamic oxaloacetic transaminase (AST), blood creatinine (Scr), urea nitrogen (BUN), and cystatin C (CysC), as well as renal function related indicators between the two groups of patients Pretherapy(P>0.05), Post-treatment, there was no change in liver function related indicators such as ALP, ALT, and AST in the two groups of patients. The observation group showed a decrease in renal function related indicators such as SCr, BUN, and CysC, and the observation group was lower than the matched group (P<0.05). Conclusion: The combination of Gusegzumab and Xiaobi Tang has a significant therapeutic effect on psoriasis vulgaris, and can reduce the level of blood cell derived inflammatory indicators in the body. The anti-inflammatory response may be related to the combination therapy further regulating the Th17/Treg balance, and increasing Xiaobi Tang treatment does not cause significant damage to the patient's liver function, which can improve the level of renal function. [ABSTRACT FROM AUTHOR]

Copyright of Progress in Modern Biomedicine is the property of Publishing House of Progress in Modern Biomedicine and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Objective: To explore and analysisi the effects of recombinant human epidermal growth factor combined with photorejuvenation M22 on skin barrier function in patients with acne pitted scars. Methods: From September 2020 to February 2022, 120 cases of patients with acne pitting scars who were diagnosed and treated in our hospital were selected as the research subjects. All the cases were divided into the combination group and the control group with 60 cases in each group, accorded to the simple allocation principle of1:1. The control group were treated with recombinant human epidermal growth factor, and the combination group were treated with photorejuvenation M22 based on the treatment of the control group. Both groups were treated and observed for 4 weeks. Results: After treatment, the total effective rates of the combination group were 88.3 %, which were higher than 66.7 % of the control group (P<0.05). The combined group had fewer clinical symptoms such as erythema regression time than the control group (P<0.05). After treatment, the proportion of skin oil in the two groups were lower than that before treatment, and the water content in the skin were higher than that before treatment (P<0.05). The depth of scar base after treatment in the two groups were significantly lower than that before treatment, and the combination group were significantly lower than that in the control group (P<0.05). The subjective and objective aesthetic scores of the two groups after treatment were higher than those before treatment, and the combination group were higher than that of the control group (P<0.05). Conclusion: Recombinant human epidermal growth factor combined with photorejuvenation M22 can improve skin barrier function in patients with acne pitting scar, can reduce the depth of scar base and the ratio of skin oil, increase skin water content, can promote the improvement of clinical symptoms, and improve skin aesthetics score, thereby improving the overall treatment effect. [ABSTRACT FROM AUTHOR]

Copyright of Progress in Modern Biomedicine is the property of Publishing House of Progress in Modern Biomedicine and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Progress in Modern Biomedicine is the property of Publishing House of Progress in Modern Biomedicine and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Objective: To study the therapeutic effect of IL-6 antibody on psoriatic mice, and to explore the effect of IL-6 antibody treatment on peripheral blood helper T cells and dendritic cells of psoriatic mice. Methods:Thirty 6-8 week old SPF grade BALB/c mice were divided into Normal group, Model group and IL-6 group according to the random number table method. The Model group and IL-6 group were used to establish psoriasis mouse models by applying imiquimod. Mice in the IL-6 group were treated by subcutaneous injection of IL-6 antibody in the dorsal alopecia. The psoriasis area and severity index (PASI), epidermal thickness and number of blood vessels in the skin lesions of the three groups of mice were compared, serum TNF-α, IL-17 and IL-23 levels, peripheral blood dendritic cells, Th17 cells and Th22 cells ratios and IL-6, IL-21 and STAT3 protein expressions in skin lesions. Results: After IL-6 antibody treatment, PASI, epidermal thickness and blood vessel number, serum TNF-α, IL-17 and IL-23 contents, peripheral blood dendritic cells and Th17 cells of mice in Model group and IL-6 group were compared. The proportions of IL-6, IL-21 and STAT3 in skin lesions were significantly higher than those in the Normal group (P<0.05); compared with the Model group, the PASI in the skin lesions of the IL-6 group mice, epidermal thickness and blood vessel number, serum TNF-α, IL-17 and IL-23 levels, peripheral blood dendritic cells, Th17 cells and Th22 cell ratios, and IL-6, IL-21 and STAT3 protein expressions in skin lesions were significantly decreased (P<0.05). Conclusion: IL-6 antibody has a good therapeutic effect on the psoriasis mouse model, and its mechanism may be related to the influence of Th17/Th22 and dendritic cell levels by inhibiting the IL-6/STAT3 pathway. [ABSTRACT FROM AUTHOR]

Copyright of Progress in Modern Biomedicine is the property of Publishing House of Progress in Modern Biomedicine and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Progress in Modern Biomedicine is the property of Publishing House of Progress in Modern Biomedicine and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

目的:探讨牛肺磷脂注射液联合呼吸机鼻塞式持续正压通气治疗新生儿呼吸窘迫综合征的疗效。方法:98例呼吸窘迫综合征新生儿为研究对象,随机数字法分为两组。对照组应用呼吸机鼻塞式持续正压通气治疗,研究组应用牛肺磷脂注射液联合治疗。结果:研究组有效率高于对照组（P<0.05）;治疗前两组患儿的动脉血气指标无明显差异,治疗后,研究组12 h及24 h后的PaO2、血pH水平高于对照组,PaCO2水平低于对照组,两组差异有统计学意义（P<0.05）;治疗前两组患儿的胸部X线情况对比无明显差异,治疗后,研究组胸部X线各项情况的改善均优于对照组,两组差异有统计学意义（P<0.05）;研究组用机时间、住院时间均短于对照组（P<0.05）;研究组并发症的发生率低于对照组,两组差异有统计学意义（P<0.05）。结论:牛肺磷脂注射液联合呼吸机鼻塞式持续正压通气治疗新生儿呼吸窘迫综合征效果理想,能够改善患儿的动脉血气指标,提高治疗的效果,缩短患儿的用机及住院时间。 [ABSTRACT FROM AUTHOR]

Copyright of Progress in Modern Biomedicine is the property of Publishing House of Progress in Modern Biomedicine and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Objective: To analyze the clinical characteristics, treatment methods and cause of death of aluminium phosphide poisoning in children. Methods: The clinical data of 55 cases of children with accidental inhalation of aluminum phosphide poisoning in our hospital from 2014 to 2018 (31 cases of mild poisoning and 14 cases of severe poisoning ) were analyzed, including the age, gender, onset seasons, poisoning inhalation time, visit time and examination results. Results: In the 55 cases, 10 cases died. The average inhalation time of mild poisoning was 25.1 hours, of which the severe poisoning was 185.4 hours, and the average visit time were 14.6 hours and 38.5 hours separately. The clinical manifestations were nausea and vomiting in 55 cases (100%), dizziness and pale in 14 cases (25%), palpitation in 16 cases (29%), respiratory failure in 14 cases (25%), severe arrhythmia in 8 cases (14.5%), hypotension and cardiogenic shock in 10 cases (18%). Electrocardiogram examination were analyzed: 1 case of supraventricular tachycardia, 4 cases of ventricular tachycardia, 1 case of grade 2 II atrioventricular block, 5 cases of sinus arrhythmia, and 26 cases of sinus tachycardia. Laboratory results followed: myocardial enzymes were elevated in 19 cases (34.5%), liver function were abnormal in 12 cases (21.8%), 6 cases (10.9%) had abnormal renal function and 14 cases (25%) had metabolic acidosis. Treatment is mainly symptomatic support treatment. All of them were severe poisoned and died from circulatory failure. Conclusion: The mortality of aluminium phosphide poisoning is very high and the cause of death is circulatory failure. There are no special detoxification drugs now, so it is important to diagnose early and treatment comprehensively. [ABSTRACT FROM AUTHOR]

Copyright of Progress in Modern Biomedicine is the property of Publishing House of Progress in Modern Biomedicine and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)